agreementsChinaDesignExamination GuidePatent Law
4 January 2023

FOLLOW UP: Amendments to the China Patent Examination Guidelines in 2022 – Part 1: New rules for designs in view of China signing onto the Hague Agreement

Since the publication of our earlier article about China signing onto the Hague Agreement, some of our Hong Kong clients have expressed interest in taking advantage of the Hague international design application system, i.e., filing a Hague international design application with the CNIPA (Chinese National Intellectual Property Administration) as a receiving office (RO).

Up until this moment, the World Intellectual Property Organization (WIPO) and the CNIPA[1] have been silent on whether a Hong Kong design applicant without a habitual residence or business office in mainland China would be eligible to file a Hague international design application with the CNIPA as a RO.

We recently brought this matter forward to the CNIPA. The CNIPA confirmed that Hong Kong applicants without a habitual residence or business office in mainland China are not eligible to file such type of application with the CNIPA.

A Hague application currently does not cover Hong Kong nor Macao

Although China is included in the current list of the contracting parties of the Hague Agreement, Hong Kong SAR and Macao SAR – both separate jurisdictions having distinct Basic Laws from the People Republic of China – are not included.

This means that Hong Kong and Macao design applicants must file independent design applications in these two regions.

Despite the current situation, things may change in the future. China’s “instrument of accession” (legal document indicating China’s agreement to join the Hague Agreement) provides room for change, stating that the current situation stands “until otherwise notified by the Government of the People’s Republic of China”[2]. This means that China has already included provisions allowing it to provide notification of changes regarding Hong Kong and Macao in the future.

Stay tuned for more upcoming articles about the other changes in the proposed Patent Examination Guidelines.

This article is for general informational purposes only and should not be considered legal advice or a legal opinion on a specific set of facts.

  1. https://www.wipo.int/hague/en/

    https://www.wipo.int/hague/memberprofiles/selectmember#/

    https://www.wipo.int/hague/en/news/2022/news_0005.html

    https://www.wipo.int/treaties/en/notifications/hague/treaty_hague_146.html

    https://wipolex.wipo.int/en/treaties/ShowResults?search_what=C&treaty_id=9

    https://www.cnipa.gov.cn/col/col2893/index.html

    https://www.cnipa.gov.cn/art/2022/10/31/art_75_180016.html

    https://www.cnipa.gov.cn/module/download/downfile.jsp?classid=0&showname=附件1:《专利审查指南修改草案(再次征求意见稿)》修改对照表.pdf&filename=dab071af523943b49eaf1114a84b6234.pdf

  2. https://www.wipo.int/hague/en/news/2022/news_0005.html

About the Authors

Polly Wong is a Patent Trainee at Eagle IP, a Boutique Patent Firm with offices in Hong Kong, Shenzhen, and Macau.

Pauli Wong is a Principal and Chinese Patent Attorney at Eagle IP, a Boutique Patent Firm with offices in Hong Kong, Shenzhen, and Macau.

Jennifer Che, J.D. is Vice President, Principal, and a US Patent Attorney at Eagle IP, a Boutique Patent Firm with offices in Hong Kong, Shenzhen, and Macau.

Other Articles

Why Do Examiners Fail to Recognize the Importance of my “Parameter Features”?

28 May 2025
The Impact of Parameter Features on Inventiveness ”Parameter features” – numerical or mathematical expressions that define the quantity or physical properties of a subject – frequently appear as technical features within a claim. Often described as numerical ranges or measurements, they frequently play a critical role in addressing technical problems. However, in practice, Examiners and […]

CNIPA further clarifies how it counts “delays” when calculating Patent Term Adjustment (PTA) in the new Draft Examination Guidelines and how it affects international applicants

12 April 2023
At the end of October 2022, the China National Intellectual Property Administration (CNIPA) released a new draft amendment of the Patent Examination Guidelines[1] (hereinafter referred to as the “New Draft”) to the new Chinese Patent Law that came into effect in 2021. We highlight two key amendments below. 1. The starting date for calculating PTA […]
Tapentadol.svg

Polymorph Patents in China: What is the Standard for Inventiveness for New Crystal Forms?

14 July 2020
This case is focused on polymorphs, namely what are the standards for novelty and inventiveness when it comes to new crystal forms of a known drug? A recent Supreme People’s Court decision in China is illustrative of the way Chinese courts are thinking about polymorph patents in China. Grünenthal is a German pharmaceutical company and […]

China Hands Down First Batch of Patent Linkage “Paragraph IV” Litigation Results

30 June 2022
China has been implementing a plethora of new laws and measures that are particularly favorable to drug companies, such as patent term extension and patent linkage. Details of the new implementation measures for patent linkage (technically “early dispute resolution mechanisms for drug patents”) came into effect on July 4, 2021. At around the same time, […]

Our Past Events

Top crossarrow-right